What happened
FDA inspected Spa De Soleil’s Sun Valley drug manufacturing facility in January 2026 and found significant CGMP violations affecting OTC topical drug production. FDA states the firm inadequately investigated 51 water-system microbiological OOL and chemical OOS results recorded from May 2024 through July 2025, including gram-negative recoveries, conductivity failures, and total organic carbon failures. Investigations relied on resampling and retesting without identifying microorganisms or adequately evaluating affected products. The water system contained dead legs, threaded fittings, Teflon tape, and ball valves, and monitoring did not reflect production schedules. FDA also found inadequate identity and impurity testing of incoming high-risk components, including controls for methanol, DEG, and EG, plus unverified reliance on supplier certificates of analysis. Manufacturing processes lacked adequate validation, and batch records omitted critical processing parameters and equipment identification. An alternative microbiological method was not shown equivalent to or better than USP methods. FDA further cited ineffective quality-unit oversight, insufficient contract-laboratory qualification, absent annual product quality evaluations, and unvalidated cleaning procedures. The February 2026 response lacked supporting documentation and adequate corrective-action evidence; similar violations had been cited in 2021.
Why it matters
From a GMP and pharmaceutical manufacturing perspective, these findings may undermine assurance that water, raw materials, processes, laboratory results, and finished products remain suitable and controlled. Inadequate investigation and microbial method validation may obscure contamination or recurring system failures. Missing component verification may leave hazardous impurities undetected, while absent process and cleaning validation may limit evidence of consistent product quality. Weak quality-unit oversight and repeated corrective-action failures may reduce confidence that deficiencies are comprehensively identified, corrected, and prevented from recurring.
Key topics: Inadequate investigation of repeated water-system OOS and microbiological OOL results, Missing identity and hazardous impurity testing for high-risk incoming components, Unvalidated manufacturing, microbiological testing, and cleaning under ineffective quality-unit oversight